Home Report Catalogue Medical Devices APAC Hepatitis Diagnostics Market Analysis
Medical Devices APAC

APAC Hepatitis Diagnostics Market Analysis, 2024–2034

APAC Hepatitis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Virus, Test, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $959.9 Mn Estimated value
Estimate 2025 $1.02 Bn 20.6% of the global market
Projected 2034 $1.77 Bn 73.3% Adds $747.9 Mn over 9 forecast years
CAGR 2025–2034 6.3% Faster than 3% of 173 Medical Devices markets here
Key players 5
  • APAC is 20.57% of the global market.
  • Among regions, the largest is North America at $2.80 Bn.
  • Fastest growing: Africa at 6.5% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$747.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hepatitis Diagnostics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $959.9 Mn — —
2025 (base) $1.02 Bn +$60.5 Mn —
2026 (forecast) $1.08 Bn +$64.3 Mn +6.3%
2027 (forecast) $1.15 Bn +$68.3 Mn +13%
2028 (forecast) $1.23 Bn +$72.6 Mn +20.1%
2029 (forecast) $1.30 Bn +$77.2 Mn +27.7%
2030 (forecast) $1.38 Bn +$82.1 Mn +35.7%
2031 (forecast) $1.47 Bn +$87.2 Mn +44.3%
2032 (forecast) $1.56 Bn +$92.7 Mn +53.4%
2033 (forecast) $1.66 Bn +$98.6 Mn +63%
2034 (forecast) $1.77 Bn +$104.8 Mn +73.3%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.96 Bn
  2. North America $2.80 Bn
  3. US $1.88 Bn
  4. APAC (this report) $1.02 Bn
  5. Europe $802.4 Mn
  6. China $366.3 Mn
  7. Canada $355.0 Mn
  8. Japan $268.0 Mn
  9. Latin America $213.0 Mn
  10. Middle East $211.9 Mn
  11. Germany $189.7 Mn
  12. France $150.9 Mn
  13. UK $141.6 Mn
  14. Italy $106.8 Mn
  15. Brazil $108.3 Mn
  16. Ecuador $102.8 Mn
  17. Saudi Arabia $100.1 Mn
  18. India $101.6 Mn
  19. Spain $89.2 Mn
  20. Mexico $81.5 Mn
  21. Africa $68.7 Mn
  22. Australia $57.6 Mn
  23. Russia $53.3 Mn
  24. New Zealand $48.4 Mn
  25. South Africa $32.9 Mn
  26. UAE $23.1 Mn
  27. Egypt $13.3 Mn
  28. Philippines $12.0 Mn
  29. Malaysia $9.0 Mn
  30. Hong Kong $8.7 Mn
  31. Thailand $6.0 Mn
  32. Singapore $5.2 Mn
  33. Kenya $3.8 Mn

The APAC Hepatitis Diagnostics Market Analysis Executive Summary

Hepatitis diagnostics detect hepatitis B and C infections and measure virus levels to guide treatment.

Key segments of the hepatitis Diagnostics market include virus (Hepatitis B, Hepatitis C and Hepatitis A) and test (Immunoassays, Molecular Tests and Rapid Tests).

APAC Hepatitis Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the hepatitis Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the hepatitis Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the hepatitis Diagnostics market.

Competitive Landscape for Hepatitis Diagnostics Market in APAC

The hepatitis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hepatitis Diagnostics Market in APAC

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how hepatitis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Hepatitis Diagnostics in APAC? Our analysts can size it for your plan. Talk to us See the public data Hepatitis B in children under 5 for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in APAC

See all
Same topic, other categories

Related on diagnostics and lab testing and hepatitis

See the topic